Published • loading... • Updated
Cilcare Announces US Clinical Trial for Tinnitus Drug, Expands Research Capacity
Summary by hearingreview.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Cilcare Announces US Clinical Trial for Tinnitus Drug, Expands Research Capacity
The company plans a clinical trial for its CIL001 tinnitus drug candidate at Massachusetts General Hospital and will triple preclinical capacity through its partnership with CBSET. Cilcare, a French-US biopharmaceutical company, announced a series of investments in the United States, including plans for a clinical trial of its tinnitus drug candidate, CIL001, and a significant expansion of its preclinical research capabilities. The announcements…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
